樂心醫療(300562.SZ):電子血壓計申報註冊獲受理
格隆匯 1 月 26日丨樂心醫療(300562.SZ)公佈,公司於近日收到廣東省藥品監督管理局發的《受理憑證》,獲知公司的電子血壓計的申報註冊已獲廣東藥監局受理(受理號:0010600120210105)。
電子血壓計產品主要由公司自主知識產權研發的主機、袖帶組成,具有藍牙、WIFI、NB-IoT通訊類型號,進一步完善血壓計產品線。產品包括氣泵模塊、MCU芯片模塊、NB-IoT模塊和電源,連接袖帶氣管插頭與主機完成血壓原始數據收集經由模擬示波算法計算得出血壓值,通過NB-IoT無線網絡自動上傳相關測量數據至智能健康雲平台進行數據的分析與整理,並形成實時的健康圖表及報吿,反饋至用户的APP或者微信公眾號綁定的相關賬號,便於用户隨時隨地瞭解個人及其家庭成員的健康數據,掌控健康趨勢。
智能電子血壓計在居家健康管理,特別是慢病管理領域的發展過程中扮演了重要角色,結合NB-IoT技術低功耗、深度覆蓋等技術優勢,提升了公司血壓計產品的省電優勢,解決了傳統產品基於GPRS無線回傳在部分區域覆蓋不好、數據難以上傳的問題,進一步優化客户的使用感。NB-IoT技術具有其他技術不具備的廣覆蓋、低功耗、大鏈接、低成本、高安全、即插即用等優勢,在智能穿戴、智慧醫療等領域有着廣泛的應用前景。
此次電子血壓計申報註冊獲得受理後,仍需廣東藥監局依法進行一系列評估和審查,公司能否順利取得該產品的註冊證有待於廣東藥監局的最終審評結論。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.